Gemcitabine-Induced Autophagy Protects Human Lung Cancer Cells from Apoptotic Death - PubMed (original) (raw)

. 2016 Dec;194(6):959-966.

doi: 10.1007/s00408-016-9936-6. Epub 2016 Sep 7.

Affiliations

• PMID: 27604425
• DOI: 10.1007/s00408-016-9936-6

Gemcitabine-Induced Autophagy Protects Human Lung Cancer Cells from Apoptotic Death

Hui-Mei Wu et al. Lung. 2016 Dec.

Abstract

Purpose: Gemcitabine has been used as a therapeutic drug combined with cisplatin for the treatment of lung cancer patients. However, the prognosis is poor due to acquired resistance. Accumulating studies have revealed that autophagy may contribute to the drug resistance. Therefore, the present study is aimed to clarify the mechanisms underlying gemcitabine-acquired resistance.

Methods: SPC-A1 and A549 cells were incubated with gemcitabine followed by assessment of cell viability with MTT assays. GFP-LC3 transient transfection, MDC staining, and transmission electron microscopy were used to detect the change of autophagy at morphological level. Flow cytometry was used to monitor the effect of 3-MA on gemcitabine-induced apoptosis. Western blot analysis was used to detect the expression of p62, LC3, Beclin-1, ATG5, activated caspase 3, Bax, BNIP3, BNIP3L, and Bcl-2.

Results: Our study showed that gemcitabine significantly induced both autophagy and apoptosis in human lung cancer cells SPC-A1 and A549. Of interest was that when autophagy was inhibited by 3-MA, the gemcitabine-induced apoptosis was effectively enhanced, suggesting that gemcitabine can activate autophagy to impair the chemosensitivity of lung cancer cells. Furthermore, the inhibition of autophagy by 3-MA further increased the expression of activated caspase 3, Bax, BNIP3, and BNIP3L, all are critical apoptotic mediators. Contrarily, 3-MA treatment further decreased the expression of Bcl-2, which is an important anti-apoptotic protein.

Conclusion: Our study indicated that autophagy protected human lung cancer cells from gemcitabine-induced apoptosis, and the combined use of gemcitabine and an autophagic inhibitor in lung cancer patients may be an effective therapeutic strategy.

Keywords: Apoptosis; Autophagy; Chemoresistance; Gemcitabine; Lung cancer.

PubMed Disclaimer

Similar articles

• Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
  Mani J, Vallo S, Rakel S, Antonietti P, Gessler F, Blaheta R, Bartsch G, Michaelis M, Cinatl J, Haferkamp A, Kögel D. Mani J, et al. BMC Cancer. 2015 Apr 7;15:224. doi: 10.1186/s12885-015-1239-4. BMC Cancer. 2015. PMID: 25885284 Free PMC article.
• The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells.
  Chen M, He M, Song Y, Chen L, Xiao P, Wan X, Dai F, Shen P. Chen M, et al. Int J Mol Med. 2014 Jul;34(1):276-82. doi: 10.3892/ijmm.2014.1772. Epub 2014 May 6. Int J Mol Med. 2014. PMID: 24804820
• Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells.
  Liu Y, Liu JH, Chai K, Tashiro S, Onodera S, Ikejima T. Liu Y, et al. J Pharm Pharmacol. 2013 Nov;65(11):1622-42. doi: 10.1111/jphp.12140. Epub 2013 Sep 15. J Pharm Pharmacol. 2013. PMID: 24102522
• Isoliquiritigenin Induces Autophagy and Inhibits Ovarian Cancer Cell Growth.
  Chen HY, Huang TC, Shieh TM, Wu CH, Lin LC, Hsia SM. Chen HY, et al. Int J Mol Sci. 2017 Sep 21;18(10):2025. doi: 10.3390/ijms18102025. Int J Mol Sci. 2017. PMID: 28934130 Free PMC article.
• The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation.
  Mukubou H, Tsujimura T, Sasaki R, Ku Y. Mukubou H, et al. Int J Oncol. 2010 Oct;37(4):821-8. doi: 10.3892/ijo_00000732. Int J Oncol. 2010. PMID: 20811703

Cited by

• Is the era of sorafenib over? A review of the literature.
  Fan G, Wei X, Xu X. Fan G, et al. Ther Adv Med Oncol. 2020 May 26;12:1758835920927602. doi: 10.1177/1758835920927602. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32518599 Free PMC article. Review.
• Challenges and Therapeutic Opportunities of Autophagy in Cancer Therapy.
  Silva VR, Neves SP, Santos LS, Dias RB, Bezerra DP. Silva VR, et al. Cancers (Basel). 2020 Nov 20;12(11):3461. doi: 10.3390/cancers12113461. Cancers (Basel). 2020. PMID: 33233671 Free PMC article. Review.
• Therapeutic potential of autophagy activators and inhibitors in lung and breast cancer- a review.
  Mudaliar P, Nalawade A, Devarajan S, Aich J. Mudaliar P, et al. Mol Biol Rep. 2022 Nov;49(11):10783-10795. doi: 10.1007/s11033-022-07711-8. Epub 2022 Jul 12. Mol Biol Rep. 2022. PMID: 35829809 Review.
• Mechanisms of resistance to chemotherapy in non-small cell lung cancer.
  Min HY, Lee HY. Min HY, et al. Arch Pharm Res. 2021 Feb;44(2):146-164. doi: 10.1007/s12272-021-01312-y. Epub 2021 Feb 19. Arch Pharm Res. 2021. PMID: 33608812 Review.
• Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting?
  Sosa Iglesias V, Giuranno L, Dubois LJ, Theys J, Vooijs M. Sosa Iglesias V, et al. Front Oncol. 2018 Jul 24;8:267. doi: 10.3389/fonc.2018.00267. eCollection 2018. Front Oncol. 2018. PMID: 30087852 Free PMC article. Review.

References

1. 1. Biochem Biophys Res Commun. 2014 Oct 24;453(3):533-8 - PubMed
2. 1. Int J Cancer. 2010 Dec 15;127(12):2918-27 - PubMed
3. 1. Annu Rev Nutr. 2007;27:19-40 - PubMed
4. 1. Lung Cancer. 2011 Nov;74(2):197-205 - PubMed
5. 1. Sci Rep. 2014 Jun 20;4:5382 - PubMed

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program